Lexaria Bioscience Corp LEXX

Alternate Symbol(s): LEXXW

Biotechnology

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.

NDAQ:LEXX - Post by User

Lexaria Bioscience Corp

Bullboard Posts

Comment by simmer1965on Nov 13, 2017 11:30pm

52 Views

Post# 26956614

RE:RE:RE:NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC

ibuprofeen kills >25,000 in the US every year due to excessive use and reulting bleeding. Ibuprofeen is also generic. If they can't get Pfizer on board to save lives then there are many generic brands that would love the opportunity.

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment